Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Azacitidine-venetoclax prolongs EFS over induction chemotherapy among induction-eligible patients with AML
Дата публикации: 14-09-2026 07:09:00

Findings from the PARADIGM study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma011.2613-08-2026
2Baseline Extracellular HMGB-1 Levels Associated with Induction Chemotherapy Response in Adult Acute Myeloid Leukemia [version 2; peer review: 2 approved with reservations]07.718-08-2026
3Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors011.901-07-2026
4Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC016.811-08-2026
5Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer014.7630-07-2026
6Successful treatment with gilteritinib for popliteal extramedullary relapse of FLT-3-ITD acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation : a case report and literature review013.2320-08-2026
7Perioperative durvalumab plus FLOT improves OS in patients with resectable gastric or GEJ adenocarcinoma09.2215-09-2026
8EMA recommends extension of therapeutic indications for sacituzumab govitecan011.118-09-2026
9Perioperative durvalumab continues to show clinical benefit in patients with resectable stage IIA to IIIB NSCLC09.2717-09-2026
10EMA recommends extension of therapeutic indications for teclistamab08.3611-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 22.5. Источник: www.esmo.org.